Sign Up to like & get
recommendations!
0
Published in 2021 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2022121
Abstract: INTRODUCTION : Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for advanced HCC. However, recent treatments with PD-1/PD-L1 inhibitor monotherapy and its combination with other therapies,…
read more here.
Keywords:
hepatocellular carcinoma;
camrelizumab investigational;
camrelizumab;
investigational agent ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2022.2033208
Abstract: ABSTRACT Introduction Programmed death 1 (PD1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte associated protein 4 (CTLA-4) are proteins involved in the modulation of immune response, which are upregulated in hepatocellular carcinoma (HCC)…
read more here.
Keywords:
hepatocellular carcinoma;
agent unresectable;
investigational agent;
durvalumab investigational ... See more keywords